Chronic Clinical Effect of Acetazolamide

• Status: Completed
• Trial end date: 2020-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The study seeks primarily to determine the chronic clinical effect of AZA on exercise capacity (6MWD) compared to placebo.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Zurich
• Treatments: Acetazolamide

Criteria

Inclusion Criteria:

• All patients undergoing right heart catheterisation (RHC) for a clinical indication and who are diagnosed with precapillary PH (mean pulmonary arterial pressure (mPAP) ≥25 mmHg, pulmonary wedge pressure (PAWP) ≤15mmHg)

• Patients have to be in a stable condition, on the same medication for >4 weeks

Exclusion Criteria:

• Patients in whom a RHC is clinically not indicated

• pregnant women

• PH in left heart disease or with more than mild chronic obstructive pulmonary disease or restrictive lung disease